KẾT QUẢ ĐIỀU TRỊ UNG THƯ BIỂU MÔ BUỒNG TRỨNG TÁI PHÁT NHẠY PLATINUM BẰNG PHÁC ĐỒ PACLITAXEL-CARBOPLATIN TẠI BỆNH VIỆN UNG BƯỚU NGHỆ AN

Abstract

Objectives: Evaluating the results of paclitaxel-carboplatin regimen in patients with platinum-sensitive recurrent ovarian cancer at Nghe An Oncology Hospital. Subjects and methods: Descriptive, retrospective, and prospective study on 44 patients with platinum-sensitive recurrent epithelial ovarian carcinoma who were treated with carboplatin plus paclitaxel at Nghe An Oncology Hospital from January 2017 to September 2022. Results: Some general characteristics of the group of patients: The mean age was 59.5 years old. The age group from 50-69 is the most common group, accounting for 79.5%. High-grade serous carcinoma was the most common histology subtype with 84.1%. 29.5% of patients relapse within 6-12 months after primary treatment and 70.5% relapse over 12 months. CA12.5 levels increased in 86.4% of patients. 43.2% of the patients underwent surgery to reduce the total tumor at recurrence. Treatment results: The response rate was 69.7% (23/33), 11 patients with complete response accounted for 33.3%, 12 patients with partial response accounted for 36.4%. Median progression-free survival was 11.1 months (95% CI: 9.4 – 2.7); Median overall survival was 30.1 months (95% CI: 18.2 – 40.0). At the end of the study, there were 20 patients alive, accounting for 45.5%. Common toxicity was hair loss, neurotoxicity, leukopenia and thrombocytopenia, almost all were grade 1-2. There were 4 patients who stopped chemotherapy due to toxicity, including 1 patient with anaphylaxis of carboplatin, 1 patient with grade 3 neurotoxicity and 2 patients with grade 3 and 4 thrombocytopenia. No patient died of toxicities. Conclusion: Paclitaxel-Carboplatin-based regimen is an effective regimen and tolerable for patients with platinum-sensitive recurrent ovarian carcinoma.